Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer.

KL, Blackwell; HJ, Burstein; AM, Storniolo; H, Rugo; G, Sledge; M, Koehler; C, Ellis; M, Casey; S, Vukelja; J, Bischoff; J, Baselga; J, O'Shaughnessy

doi:10.1200/jco.2008.21.4437

Public

Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer.

Shared by NobleBlocks on Feb 1, 2010 • 12:00 AM UTC

Authors:

Blackwell KL

Burstein HJ

Storniolo AM

Abstract

Purpose Preclinical studies in ErbB2-positive cell lines demonstrated a synergistic interaction between lapatinib and trastuzumab, suggesting that dual blockade is more effective than a single agent alone. EGF104900 compared the activity of lapatinib alone or in combination with trastuzumab in patie...

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!